Palo Alto, CA, United States of America

Malissa Takahashi


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 78(Granted Patents)


Location History:

  • Sunnyvale, CA (US) (2012)
  • Palo Alto, CA (US) (2017)

Company Filing History:


Years Active: 2012-2017

Loading Chart...
2 patents (USPTO):

Title: Malissa Takahashi - Innovations in Fluidic Sample Processing

Introduction

Malissa Takahashi is an innovative inventor based in Palo Alto, California. With a strong focus on medical applications, she holds two patents that contribute significantly to the field of fluidic sample processing. Her work plays a crucial role in advancing point-of-care testing technologies.

Latest Patents

Malissa's latest patents revolve around systems and methods of fluidic sample processing. These inventions provide fluidic devices and systems that enable the detection of analytes from biological fluids. They are particularly useful for point-of-care testing across various medical applications, showcasing her commitment to improving healthcare diagnostics.

Career Highlights

Malissa is currently employed at Theranos, Inc., a company recognized for its groundbreaking approach to blood testing and diagnostics. During her career, she has made notable contributions to the tech and medical fields, focusing on innovations that streamline the testing processes and enhance healthcare outcomes.

Collaborations

Throughout her professional journey, Malissa has collaborated with notable coworkers such as Shaunak Roy and Ian Gibbons. These partnerships exemplify the dynamic teamwork that characterizes her work environment and highlights the importance of collaboration in driving innovation.

Conclusion

Malissa Takahashi is a prominent figure in the realm of medical innovations, specifically in fluidic sample processing. Her patents not only reflect her inventive spirit but also contribute to the advancement of healthcare technology. As she continues her work at Theranos, Inc., her influence in the field of medical diagnostics is expected to grow even further.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…